Gladding P - Search Results

1

The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.

Panattoni L, Brown PM, Te Ao B, Webster M, Gladding P. Panattoni L, et al. Among authors: gladding p. Pharmacoeconomics. 2012 Nov 1;30(11):1067-84. doi: 10.2165/11595080-000000000-00000. Pharmacoeconomics. 2012. PMID: 22974536

2

Prasugrel, Māori, and personalised medicine in New Zealand.

Gladding P, White H, Webster M. Gladding P, et al. N Z Med J. 2010 Mar 5;123(1310):86-90. N Z Med J. 2010. PMID: 20360782

3

Correction to: The Cost Effectiveness of Genetic Testing for CYP2C19 Variants to Guide Thienopyridine Treatment in Patients with Acute Coronary Syndromes.

Panattoni L, Brown PM, Ao BT, Webster M, Gladding P. Panattoni L, et al. Among authors: gladding p. Pharmacoeconomics. 2020 Mar;38(3):315. doi: 10.1007/s40273-020-00885-8. Pharmacoeconomics. 2020. PMID: 31960352

4

Antiplatelet drug nonresponsiveness.

Gladding P, Webster M, Ormiston J, Olsen S, White H. Gladding P, et al. Am Heart J. 2008 Apr;155(4):591-9. doi: 10.1016/j.ahj.2007.12.034. Am Heart J. 2008. PMID: 18371464 Review.

5

Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.

Gladding P, White H, Voss J, Ormiston J, Stewart J, Ruygrok P, Bvaldivia B, Baak R, White C, Webster M. Gladding P, et al. JACC Cardiovasc Interv. 2009 Nov;2(11):1095-101. doi: 10.1016/j.jcin.2009.08.018. JACC Cardiovasc Interv. 2009. PMID: 19926050 Free article.

6

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial.

Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML. Gladding P, et al. JACC Cardiovasc Interv. 2008 Dec;1(6):620-7. doi: 10.1016/j.jcin.2008.09.008. JACC Cardiovasc Interv. 2008. PMID: 19463375 Free article. Clinical Trial.

7

Clopidogrel and stent thrombosis after percutaneous coronary intervention.

Gladding P, Webster M. Gladding P, et al. N Z Med J. 2007 Jun 1;120(1255):U2554. N Z Med J. 2007. PMID: 17546102 No abstract available.

8

The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial.

Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, Ormiston J, El-Jack S, Armstrong G, Kay P, Scott D, Gunes A, Dahl ML. Gladding P, et al. JACC Cardiovasc Interv. 2008 Dec;1(6):612-9. doi: 10.1016/j.jcin.2008.09.005. JACC Cardiovasc Interv. 2008. PMID: 19463374 Free article. Clinical Trial.

9

Prasugrel STEMI subgroup analysis.

Webster MW, Gladding P. Webster MW, et al. Among authors: gladding p. Lancet. 2009 May 30;373(9678):1846; author reply 1846-8. doi: 10.1016/S0140-6736(09)61020-5. Lancet. 2009. PMID: 19482210 No abstract available.

10

Late drug-eluting stent thrombosis and erythropoietin: cause and effect?

Gladding PA, Webster MW, Kay P. Gladding PA, et al. Heart Lung Circ. 2007 Aug;16(4):305-7. doi: 10.1016/j.hlc.2007.01.002. Epub 2007 Apr 18. Heart Lung Circ. 2007. PMID: 17446131

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters